Prostate Cancer Imaging

前列腺癌是美国男性最常见的癌症，但目前还没有令人满意的影像学方法来定位前列腺内的前列腺癌。一种成功定位前列腺癌的成像方法可以用于诊断、指导治疗和监测复发。我们已经建立了一个由泌尿科医生、放射肿瘤学家、诊断放射科医生、磁共振工程师和物理学家组成的多学科团队，在3Tesla开发先进的前列腺磁共振成像方法。患者通过直肠内线圈、高分辨率T2加权MRI、磁共振波谱和动态增强MRI进行扫描。结果被合成为多参数图像，然后与活检或解剖标本进行比较。这种材料，反过来由迈克尔·艾默特-巴克博士的实验室研究，以确定潜在的新的细胞表面标记。这些标记物可能在未来用于开发下一代前列腺癌靶向成像。这项研究的一个独特之处在于，癌细胞相对于腺体其余部分的空间完整性得以保持，因此细胞表面标记物数据与MRI在空间上是相关的。此外，我们还参与MR引导下的前列腺活检。在MIP实验室，我们正在基于Emmert Buck博士的发现开发下一代分子靶向显像剂。人类异种肿瘤模型用于测试靶向探针的有效性（例如111In标记的PSMA抗体，Cy5.5标记的PSMA适体等）。

Prostate cancer is the most commonly diagnosed cancer in American men yet there are no satisfactory imaging methods for localizing prostate cancer within the gland. An imaging method that successfully localized prostate cancers could be useful for diagnosis, directing therapy and monitoring for recurrence. We have developed a multidisciplinary team of urologists, radiation oncologists, diagnostic radiologists, MR engineers and physicists to develop advanced methods of prostate imaging with MRI at 3Tesla. Patients are scanned with an endorectal coil and high resolution T2 weighted MRI, MR spectroscopy and dynamic contrast enhanced MRI are performed. The results are synthesized to a multiparametric image that is then compared with the biopsy or anatomic specimen. This material, in turn is investigated by the laboratory of Dr. Michael Emmert-Buck to identify potential novel cell surface markers. These markers may be used in the future to develop the next generation of prostate cancer targeted imaging. A unique aspect of this research is that spatial integrity of the cancer with respect to the rest of the gland is maintained so that the cell surface marker data is spatially correlated with MRI. Additionally, we participate in MR guided biopsies of the prostate. In the MIP laboratory we are developing the next generation of molecularly targeted imaging agents based on the findings of Dr. Emmert Buck. Human xenograft tumor models are used to test the efficacy of targed probes (e.g. 111In labeled PSMA antibody, Cy5.5 labeled PSMA aptamer among others).